Anti-NALCN/ CLIFAHDD/ CanIon monoclonal antibody

Anti-NALCN/ CLIFAHDD/ CanIon antibody for FACS & in-vivo assay

Target products collectionGo to NALCN/NALCN products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0863-Ab-1/ GM-Tg-hg-MP0863-Ab-2Anti-Human NALCN monoclonal antibodyHuman
GM-Tg-rg-MP0863-Ab-1/ GM-Tg-rg-MP0863-Ab-2Anti-Rat NALCN monoclonal antibodyRat
GM-Tg-mg-MP0863-Ab-1/ GM-Tg-mg-MP0863-Ab-2Anti-Mouse NALCN monoclonal antibodyMouse
GM-Tg-cynog-MP0863-Ab-1/ GM-Tg-cynog-MP0863-Ab-2Anti-Cynomolgus/ Rhesus macaque NALCN monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0863-Ab-1/ GM-Tg-felg-MP0863-Ab-2Anti-Feline NALCN monoclonal antibodyFeline
GM-Tg-cang-MP0863-Ab-1/ GM-Tg-cang-MP0863-Ab-2Anti-Canine NALCN monoclonal antibodyCanine
GM-Tg-bovg-MP0863-Ab-1/ GM-Tg-bovg-MP0863-Ab-2Anti-Bovine NALCN monoclonal antibodyBovine
GM-Tg-equg-MP0863-Ab-1/ GM-Tg-equg-MP0863-Ab-2Anti-Equine NALCN monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0863-Ab-1/ GM-Tg-hg-MP0863-Ab-2; GM-Tg-rg-MP0863-Ab-1/ GM-Tg-rg-MP0863-Ab-2;
GM-Tg-mg-MP0863-Ab-1/ GM-Tg-mg-MP0863-Ab-2; GM-Tg-cynog-MP0863-Ab-1/ GM-Tg-cynog-MP0863-Ab-2;
GM-Tg-felg-MP0863-Ab-1/ GM-Tg-felg-MP0863-Ab-2; GM-Tg-cang-MP0863-Ab-1/ GM-Tg-cang-MP0863-Ab-2;
GM-Tg-bovg-MP0863-Ab-1/ GM-Tg-bovg-MP0863-Ab-2; GM-Tg-equg-MP0863-Ab-1/ GM-Tg-equg-MP0863-Ab-2
Products NameAnti-NALCN monoclonal antibody
Formatmab
Target NameNALCN
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NALCN benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NALCN/ CLIFAHDD/ CanIon VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0863
    Target NameNALCN
    Gene ID259232,338370,266760,106994360,485535,101081601,536103,100062714
    Gene Symbol and SynonymsA530023G15Rik,bA430M15.1,CanIon,CLIFAHDD,IHPRF,IHPRF1,INNFD,NALCN,VGCNL1
    Uniprot AccessionQ8IZF0,Q6Q760
    Uniprot Entry NameNALCN_HUMAN,NALCN_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000102452
    Target ClassificationN/A

    The target: NALCN, gene name: NALCN, also named as CLIFAHDD, CanIon, IHPRF, IHPRF1, INNFD, VGCNL1, bA430M15.1. This gene encodes a voltage-independent, nonselective cation channel which belongs to a family of voltage-gated sodium and calcium channels that regulates the resting membrane potential and excitability of neurons. This family is expressed throughout the nervous system and conducts a persistent sodium leak current that contributes to tonic neuronal excitability. The encoded protein forms a channelosome complex that includes G-protein-coupled receptors, UNC-79, UNC-80, NCA localization factor-1, and src family tyrosine kinases. Naturally occurring mutations in this gene are associated with infantile neuroaxonal dystrophy, infantile hypotonia with psychomotor retardation and characteristic facies (IHPRF) syndrome, and congenital contractures of the limbs and face with hypotonia and developmental delay (CLIFAHDD) syndrome. A knockout of the orthologous gene in mice results in paralysis with a severely disrupted respiratory rhythm, and lethality within 24 hours after birth. [provided by RefSeq, Apr 2017].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.